Did Merck & Co. Inc (NYSE:MRK) Say Something On Clinical Trial Program?
On Thursday, Merck & Co., Inc (NYSE:MRK) provided the overview of a clinical-trial program for V503. This is its investigational 9-Valent human-papillomavirus vaccine. This review was provided to the United States’ Advisory Committee on Immunization Practices. The company said that it has completed the pivotal efficacy-trial and that all the primary end-points of the trial have been met successfully. Merck & Co., Inc (NYSE:MRK) expects to submit the Biologics License Application for this drug to the United States Food and Drug Administration this year.
This study evaluated the immunogenicity, efficacy and the safety of the drug in women between 1- and 26 years of age. The company plans to present these results and some other results from its Phase-III clinical-program for V503 in November, at EUROGIN.
In Thursday’s trading, Merck & Co., Inc (NYSE:MRK) dropped by 0.73%. The opening price of the shares was $46.80, which climbed to an intraday high of $46.86 and dipped to a close of $46.22. Approximately 11.20 million shares were traded on Thursday while an average volume of 13.98 million shares were traded over a 30 day period. The 52-week low of Merck & Co., Inc (NYSE:MRK) shares is $40.02 and its 52-week high is $50.16. The company has a market capitalization of $135.26 billion.
About the company
Merck & Co., Inc (NYSE:MRK) is a global healthcare company. It delivers health-solutions via its prescription vaccines, medicines, biologic-therapies, animal-health, & consumer-care products. The company markets all these products directly & via its joint ventures. Merck & Co., Inc (NYSE:MRK) has 4 business segments. 1- Pharmaceutical, 2- Animal Health, 3- Consumer Care and 4- Alliances segments. The company also has 1 reportable segment- the Pharmaceutical segment. This Pharmaceutical segment covers human health pharmaceutical & vaccine products that are marketed either directly by Merck & Co., Inc (NYSE:MRK) or via various joint ventures.